Skip to main content

Scientific Research in

The Air Liquide Foundation aims to support scientific research on improving the respiratory function, especially in the medical sector and in exploration (space, deep-sea diving, or sport).


Supported projects by the Foundation since its creation in 2008

© Philippe Voisin - Premup

Support for research on the respiratory illnesses of preterm infants

Today, in France, 20% of pregnancies are pathological that is to say that they endanger mother’s or child’s health. These cases are mainly caused by preterm birth and intrauterine growth retardation. Premature birth is at the origin of half of all disabilities at birth. Intrauterine growth retardation also gives rise to many others late-emerging diseases like obesity, diabetes, high-blood pressure and cardiovascular disease. The Air Liquide Foundation has supported two research projects led by the PremUP Foundation that focus on respiratory diseases in preterm infants.

The PremUp Foundation received the Air Liquide Foundation award for scientific research on health and breathing 2016.

preterm birth and intrauterine growth retardation are at the origin of half of all disabilities at birth

The 2016 Air Liquide Foundation Awards: interview of Dr. Daniele Evain-Brion, PremUp Foundation

Expédition au coeur de l’Himalaya, sur les pentes du Manaslu (8163 m) © EXALT - Samuel Vergès

Improving Oxygenation at High Altitude

The Air Liquide Foundation supports a research project led by the Centre d’Expertise en Altitude (EXALT) regarding oxygenation in high altitude environments.The study tracked fifty volunteers in the Himalayan mountains, about 5500 meters above sea level, and measured cerebral and cardiac effects at high altitudes and also sleep cycle changes. A mask that increases expiratory pressure was also experimented, with the goal of raising blood oxygen concentration and thus facilitating the adaptation of organisms at high altitude.

The Air Liquide Foundation aided in the analysis of data collected during the expedition to Nepal as well as in the creation of this prototype pressurized expiration mask.
© T Rupp
Pressurized expiration mask enabling high-altitude adaptation © EXALT - Thomas Rupp

Develop a new therapeutic way against cystic fibrosis

Cystic fibrosis is the most common fatal genetic disease in western countries. It affects one out of every 2,500 births and patients have a 35-year life expectancy. There is currently no cure for cystic fibrosis. The Université Libre de Bruxelles studies the possibility for a treatment thanks to the discovery of a new type of antibodies, the nanobodies, smaller than usual antibodies.

this therapeutic approach would eliminate most symptoms of the disease, including respiratory symptoms
© Fondation Air Liquide

Air Liquide Foundation

Discover supported projects